These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35538439)

  • 1. Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy.
    Le WB; Shi JS; Gong SW; Yang F
    BMC Nephrol; 2022 May; 23(1):179. PubMed ID: 35538439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of Tripterygium wilfordii Hook F in the immunosuppressive treatment of IgA nephropathy.
    Chen YZ; Gao Q; Zhao XZ; Chen XM; Zhang F; Chen J; Xu CG; Sun LL; Mei CL
    Intern Med; 2010; 49(19):2049-55. PubMed ID: 20930429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Tripterygium wilfordii Induction Therapy to IgA Nephropathy Patients with Heavy Proteinuria.
    Wang Z; Yu C; Zhou LN; Chen X
    Biol Pharm Bull; 2017 Nov; 40(11):1833-1838. PubMed ID: 28867717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Kunxian Capsule, a Novel Tripterygium Preparation be Used as an Adjuvant Treatment of Early Recurrent Focal Segmental Glomerular Sclerosis After Renal Transplantation? A Case Report.
    Sa R; Guo Z; Zhao G; Zhao D; Guo H; Chen G; Zhu L
    Transplant Proc; 2023 Apr; 55(3):649-653. PubMed ID: 36948963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of effects and safety of Tripterygium wilfordii polyglycoside in the treatment of IgA nephropathy.
    Wang RX; Liao BQ; Chen W; Zhang YM; Tang XH; Xie FH
    Eur Rev Med Pharmacol Sci; 2022 Dec; 26(23):8756-8770. PubMed ID: 36524494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism for the therapeutic effect of
    Zhao J; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 May; 47(5):573-582. PubMed ID: 35753727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR.
    Xiong C; Li L; Bo W; Chen H; XiaoWei L; Hongbao L; Peng Z
    J Formos Med Assoc; 2020 Mar; 119(3):685-692. PubMed ID: 31801679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of
    Cheng Y; Liu Y; Lin L; Li D; Peng L; Zheng K; Tao J; Li M
    Ren Fail; 2024 Dec; 46(1):2295425. PubMed ID: 38178377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome.
    Chen Y; Gong Z; Chen X; Tang L; Zhao X; Yuan Q; Cai G
    Cochrane Database Syst Rev; 2013 Aug; (8):CD008568. PubMed ID: 23934958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Based on Network Pharmacology Tools to Investigate the Mechanism of
    Xia M; Liu D; Liu H; Zhao J; Tang C; Chen G; Liu Y; Liu H
    Front Med (Lausanne); 2021; 8():794962. PubMed ID: 34977095
    [No Abstract]   [Full Text] [Related]  

  • 11.
    Lengnan X; Ban Z; Haitao W; Lili L; Aiqun C; Huan W; Ping Z; Yonghui M
    Biomed Res Int; 2020; 2020():9181037. PubMed ID: 32596393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association of Glomerular Glucocorticoid Receptor Expression with Responsiveness to Corticosteroid Treatment in IgA Nephropathy.
    Kee YK; Nam BY; Jhee JH; Park JT; Lim BJ; Yoo TH; Kang SW; Jeong HJ; Han SH
    Am J Nephrol; 2019; 50(3):187-195. PubMed ID: 31408863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy.
    Hu T; Liu Q; Xu Q; Liu H; Qiu W; Huang F; Zhang S; Lv Y
    Medicine (Baltimore); 2018 May; 97(18):e0610. PubMed ID: 29718866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.
    Pozzi C; Andrulli S; Del Vecchio L; Melis P; Fogazzi GB; Altieri P; Ponticelli C; Locatelli F
    J Am Soc Nephrol; 2004 Jan; 15(1):157-63. PubMed ID: 14694168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial.
    Ge Y; Xie H; Li S; Jin B; Hou J; Zhang H; Shi M; Liu Z
    J Transl Med; 2013 May; 11():134. PubMed ID: 23725518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy.
    Zhang Q; Shi SF; Zhu L; Lv JC; Liu LJ; Chen YQ; Zhang H; Wang HY
    Am J Nephrol; 2012; 35(4):312-20. PubMed ID: 22456060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Active Compounds and Therapeutic Target of
    Liu P; Zhang J; Wang Y; Shen Z; Wang C; Chen DQ; Qiu X
    Front Med (Lausanne); 2021; 8():747922. PubMed ID: 34621768
    [No Abstract]   [Full Text] [Related]  

  • 19. Spontaneous remission in adult patients with IgA nephropathy treated with conservative therapy.
    Sato H; Ichikawa D; Okada E; Suzuki T; Watanabe S; Shirai S; Shibagaki Y
    PLoS One; 2021; 16(5):e0251294. PubMed ID: 34043669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgA nephropathy with presentation of nephrotic syndrome at onset in children.
    Shima Y; Nakanishi K; Sato M; Hama T; Mukaiyama H; Togawa H; Tanaka R; Nozu K; Sako M; Iijima K; Suzuki H; Yoshikawa N
    Pediatr Nephrol; 2017 Mar; 32(3):457-465. PubMed ID: 27714465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.